Login / Signup

Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α.

Beatrice MacchiEmanuela BalestrieriCaterina FrezzaSandro GrelliElena VallettaAmbroise MarçaisFrancesca Marino-MerloJocelyn TurpinCharles R M BanghamOlivier HermineAntonio MastinoAli Bazarbachi
Published in: Blood advances (2017)
The therapeutic efficacy of the AZT and IFN combination in ATL presumably reflects the inhibition of RT-related functions.HTLV-1-RT activity from short-term cultured PBMCs may represent a predictive correlate of clinical response to AZT/IFN in ATL patients.
Keyphrases
  • dendritic cells
  • end stage renal disease
  • immune response
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes